Preferred Label : Anti-PD-L1 Antibody/IL-15 Fusion Protein IGM-7354;
NCIt synonyms : IL-15/IL-15Ra Anti-PD-L1 IgM Antibody Fusion Protein IGM-7354; PD-L1-targeted IL-15 Immunocytokine IGM-7354; Immunocytokine IGM-7354;
NCIt definition : A fusion protein composed of a pentameric immunoglobulin M (IgM) antibody directed
against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster
of differentiation 274; CD274) fused to interleukin (IL)-15/IL-15 receptor alpha (IL-15Ra)
complex, with potential immunostimulatory and antineoplastic activities. Upon administration
of the anti-PD-L1 antibody/IL-15 fusion protein IGM-7354, the anti-PD-L1 antibody
moiety specifically targets and binds to PD-L1 expressing cancer cells and antigen
presenting cells (APCs) in the tumor microenvironment (TME), thereby delivering IL-15
to PD-L1-expressing tumor cells. In turn, the IL-15 stimulates the proliferation of
natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally,
and reverses T-cell exhaustion. This induces an anti-tumor immune response in the
TME against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein, is expressed
on APCs and on various cancer cell types. PD-L1 binding to PD-1, a negative regulator
of the immune system on activated T-cells, limits the expansion and survival of CD8-positive
T-cells, suppresses the immune system and results in immune evasion. The immunostimulatory
cytokine IL-15 regulates CD8 T- and NK cell development, activation, and proliferation.
IL-15Ra complexed with IL-15 increases the half-life of IL-15. By binding to PD-L1-expressing
cells in the TME, IGM-7354 enhances its IL-15-mediated activity on the immune system
locally and increases its efficacy while reducing systemic toxicities.;
Molecule name : IGM 7354; IGM-7354;
NCI Metathesaurus CUI : CL1907396;
Origin ID : C200375;
concept_is_in_subset
- has_target
